Advertisement

Challenges and Opportunities in Social Epigenomics and Cancer

  • Krishna Banaudha
  • Vineet Kumar
  • Mukesh Verma
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1856)

Abstract

Social epigenomics is an area of science that evaluates why and how different social factors and processes affect different components of the epigenome. As it happens with most of the new areas in science, social epigenetics being a relatively new area, only limited progress has been made. However, the potential of implicating social epigenomics in improving health and health related policies is tremendous. Epidemiologic studies evaluating social, behavior, family, and environmental factors have helped understand social inequality and develop the area of social epigenomics. Most of the information in social epidemiology has been gathered from genetic studies. Now the time has come that we may apply similar approaches in social epigenomics because technologies of determining methylation, histone, and noncoding RNA profiling are well developed. The focus of this chapter is to understand the role of epigenetic regulation in social experiences at various stages in life due to altered function of genes and affecting health in populations with different races/ethnicity. Here we discuss the current challenges and opportunities in the field.

Key words

Chromatin Epigenetics Health disparity Methylation Social epigenomics 

Abbreviations

DNMT

DNA methyl transferase

ER

Estrogen receptor

HAT

Histone acetyl transferase

HDAC

Histone deacetylase

PR

Progesterone receptor

Notes

Acknowledgments

We are thankful to the program staff for reading the manuscript and providing suggestions to improve the manuscript.

References

  1. 1.
    Raghuraman S, Donkin I, Versteyhe S, Barres R, Simar D (2016) The emerging role of epigenetics in inflammation and immunometabolism. Trends Endocrinol Metab 27(11):782–795Google Scholar
  2. 2.
    Dabritz J, Menheniott TR (2014) Linking immunity, epigenetics, and cancer in inflammatory bowel disease. Inflamm Bowel Dis 20(9):1638–1654Google Scholar
  3. 3.
    Fernandez-Rhodes L, Gong J, Haessler J, Franceschini N, Graff M, Nishimura KK, Wang Y, Highland HM, Yoneyama S, Bush WS, Goodloe R, Ritchie MD, Crawford D, Gross M, Fornage M, Buzkova P, Tao R, Isasi C, Aviles-Santa L, Daviglus M, Mackey RH, Houston D, Gu CC, Ehret G Nguyen KH, Lewis CE, Leppert M, Irvin MR, Lim U, Haiman CA, Le Marchand L, Schumacher F, Wilkens L, Lu Y, Bottinger EP, Loos RJL, Sheu WH, Guo X, WJ L, Y H, Hung YJ, Absher D, Wu IC, Taylor KD, Lee IT, Liu Y, Wang TD, Quertermous T, Juang JJ, Rotter JI, Assimes T, Hsiung CA, Chen YI, Prentice R, Kuller LH, Manson JE, C K, Smokowski P, Robinson WR, Gordon-Larsen P, Li R, Hindorff L, Buyske S, Matise TC, Peters U, North KE (2017) Trans-ethnic fine-mapping of genetic loci for body mass index in the diverse ancestral populations of the Population Architecture using Genomics and Epidemiology (PAGE) study reveals evidence for multiple signals at established loci. Hum Genet 136(6):771–800Google Scholar
  4. 4.
    Li W, Guo Y, Zhang C, Wu R, Yang AY, Gaspar J, Kong AN (2016) Dietary phytochemicals and cancer chemoprevention: a perspective on oxidative stress, inflammation, and epigenetics. Chem Res Toxicol 29(12):2071–2095Google Scholar
  5. 5.
    Li Y, Tollefsbol TO (2016) Age-related epigenetic drift and phenotypic plasticity loss: implications in prevention of age-related human diseases. Epigenomics 8(12):1637–1651Google Scholar
  6. 6.
    Tejeda S, Stolley MR, Vijayasiri G, Campbell RT, Ferrans CE, Warnecke RB, Rauscher GH (2017) Negative psychological consequences of breast cancer among recently diagnosed ethnically diverse women. Psychooncology.  https://doi.org/10.1002/pon.4456
  7. 7.
    Muhsen K, Green MS, Soskolne V, Neumark Y (2017) Inequalities in non-communicable diseases between the major population groups in Israel: achievements and challenges. Lancet 389(10088):2531–2541Google Scholar
  8. 8.
    Malta DC, Bernal RT, de Souza MF, Szwarcwald CL, Lima MG, Barros MB (2016) Social inequalities in the prevalence of self-reported chronic non-communicable diseases in Brazil: national health survey 2013. Int J Equity Health 15(1):153Google Scholar
  9. 9.
    Fang D, Gan H, Lee JH, Han J, Wang Z, Riester SM, Jin L, Chen J, Zhou H, Wang J, Zhang H, Yang N, Bradley EW, Ho TH, Rubin BP, Bridge JA, Thibodeau SN, Ordog T, Chen Y, van Wijnen AJ, Oliveira AM, Xu RM, Westendorf JJ, Zhang Z (2016) The histone H3.3K36M mutation reprograms the epigenome of chondroblastomas. Science 352(6291):1344–1348Google Scholar
  10. 10.
    Ropero S, Esteller M (2007) The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 1(1):19–25Google Scholar
  11. 11.
    Salmanidis M, Pillman K, Goodall G, Bracken C (2014) Direct transcriptional regulation by nuclear microRNAs. Int J Biochem Cell Biol 54:304–311Google Scholar
  12. 12.
    Chitnis NS, Pytel D, Bobrovnikova-Marjon E, Pant D, Zheng H, Maas NL, Frederick B, Kushner JA, Chodosh LA, Koumenis C, Fuchs SY, Diehl JA (2012) miR-211 is a prosurvival microRNA that regulates chop expression in a PERK-dependent manner. Mol Cell 48(3):353–364Google Scholar
  13. 13.
    Hong CC, Chen PS, Chiou J, Chiu CF, Yang CY, Hsiao M, Chang YW, Yu YH, Hung MC, Hsu NW, Shiah SG, Hsu NY, Su JL (2014) miR326 maturation is crucial for VEGF-C-driven cortactin expression and esophageal cancer progression. Cancer Res 74(21):6280–6290Google Scholar
  14. 14.
    Wang W, Ren F, Wu Q, Jiang D, Li H, Shi H (2014) MicroRNA-497 suppresses angiogenesis by targeting vascular endothelial growth factor A through the PI3K/AKT and MAPK/ERK pathways in ovarian cancer. Oncol Rep 32(5):2127–2133Google Scholar
  15. 15.
    Xu J, Wang T, Cao Z, Huang H, Li J, Liu W, Liu S, You L, Zhou L, Zhang T, Zhao Y (2014) MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis. Oncotarget 5(16):6983–6993Google Scholar
  16. 16.
    King KE, Kane JB, Scarbrough P, Hoyo C, Murphy SK (2016) Neighborhood and family environment of expectant mothers may influence prenatal programming of adult cancer risk: discussion and an illustrative DNA methylation example. Biodemography Soc Biol 62(1):87–104Google Scholar
  17. 17.
  18. 18.
    Acharya S, Xu J, Wang X, Jain S, Wang H, Zhang Q, Chang CC, Bower J, Arun B, Seewaldt V, Yu D (2016) Downregulation of GLUT4 contributes to effective intervention of estrogen receptor-negative/HER2-overexpressing early stage breast disease progression by lapatinib. Am J Cancer Res 6(5):981–995Google Scholar
  19. 19.
    Dietze EC, Sistrunk C, Miranda-Carboni G, O'Regan R, Seewaldt VL (2015) Triple-negative breast cancer in African-American women: disparities versus biology. Nat Rev Cancer 15(4):248–254Google Scholar
  20. 20.
    Benevolenskaya EV, Islam AB, Ahsan H, Kibriya MG, Jasmine F, Wolff B, Al-Alem U, Wiley E, Kajdacsy-Balla A, Macias V, Rauscher GH (2016) DNA methylation and hormone receptor status in breast cancer. Clin Epigenetics 8:17Google Scholar
  21. 21.
    Song MA, Brasky TM, Marian C, Weng DY, Taslim C, Dumitrescu RG, Llanos AA, Freudenheim JL, Shields PG (2015) Racial differences in genome-wide methylation profiling and gene expression in breast tissues from healthy women. Epigenetics 10(12):1177–1187Google Scholar
  22. 22.
    Kamali P, Zettervall SL, Wu W, Ibrahim AM, Medin C, Rakhorst HA, Schermerhorn ML, Lee BT, Lin SJ (2017) Differences in the reporting of racial and socioeconomic disparities among three large national databases for breast reconstruction. Plast Reconstr Surg 139(4):795–807Google Scholar
  23. 23.
    Grontved L, Bandle R, John S, Baek S, Chung HJ, Liu Y, Aguilera G, Oberholtzer C, Hager GL, Levens D (2012) Rapid genome-scale mapping of chromatin accessibility in tissue. Epigenetics Chromatin 5(1):10Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Krishna Banaudha
    • 1
  • Vineet Kumar
    • 2
  • Mukesh Verma
    • 3
  1. 1.Department of Biochemistry and Molecular Biology, School of Medicine and Public HealthGeorge Washington UniversityWashingtonUSA
  2. 2.Department of PharmacologyNational University of SingaporeSingaporeSingapore
  3. 3.Epidemiology and Genomics Research ProgramNational Cancer InstituteRockvilleUSA

Personalised recommendations